Evidence map›Paper›PMID 29554282›Full record

Trial reportJournal of the National Cancer Institute2018

Effects of Celecoxib and Low-dose Aspirin on Outcomes in Adjuvant Aromatase Inhibitor-Treated Patients: CCTG MA.27.

Kathrin Strasser-Weippl, Michaela J Higgins, Judith-Anne W Chapman, James N Ingle, George W Sledge, George T Budd, Matthew J Ellis, Kathleen I Pritchard, Mark J Clemons, Tanja Badovinac-Crnjevic and 6 more

Open access · bronzeAbstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of the National Cancer Institute, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 3 pooled it
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 3 syntheses or guidelines pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Decorin deficiency promotes epithelial-mesenchymal transition and colon cancer metastasis.Matrix biology : journal of the International Society for Matrix Biology · 2021
    Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Partners in Crime: Fledgling Tumors Hijack Inflammation.Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research · 2019
    Article
  18. NSAIDs to Prevent Breast Cancer Recurrence? An Unanswered Question.Journal of the National Cancer Institute · 2018
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 13 institutions in 5 countries.

Kathrin Strasser-WeipplCenter for Oncology, Hematology and Palliative Care, Wilhelminen Hospital, Vienna, Austria.
Michaela J HigginsMater Misericordiae University Hospital, Dublin, Ireland.
Judith-Anne W ChapmanCanadian Cancer Trials Group, Queen's University, Kingston, ON, Canada.
James N IngleDivision of Medical Oncology, Mayo Clinic, Rochester, MN.
George W SledgeStanford University Medical Center, Stanford, CA.
George T BuddTaussig Cancer Center, Cleveland Clinic, Cleveland, OH.
Matthew J EllisLester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX.
Kathleen I PritchardSunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada.
Mark J ClemonsDivision of Medical Oncology, Department of Medicine, University of Ottawa, Ottawa, ON, Canada.
Tanja Badovinac-CrnjevicHoffman-La Roche, Basel, Switzerland.
Lei HanCenter for Oncology, Hematology and Palliative Care, Wilhelminen Hospital, Vienna, Austria.
Karen A GelmonBritish Columbia Cancer Agency, Vancouver, BC, Canada.
Manuela RabaglioInternational Breast Cancer Study Group Coordinating Center, Inselspital, Berne, Switzerland.
Catherine ElliottCenter for Oncology, Hematology and Palliative Care, Wilhelminen Hospital, Vienna, Austria.
Lois E ShepherdCenter for Oncology, Hematology and Palliative Care, Wilhelminen Hospital, Vienna, Austria.
Paul E GossMassachusetts General Hospital, Harvard Medical School, Boston, MA.
Wilhelminen Hospital · ATBaylor College of Medicine · USBC Cancer Agency · CACleveland Clinic · USInternational Breast Cancer Study Group · CHMassachusetts General Hospital · USMater Misericordiae University Hospital · IEMayo Clinic in Arizona · USQueen's University · CARoche (Switzerland) · CHStanford University · USSunnybrook Health Science Centre · CAUniversity of Ottawa · CA

Funding

NCIC Clinical Trials Group - Canadian Collaborating Clinical Trials NetworkU10CA180863 · NCI · QUEEN'S UNIVERSITY AT KINGSTON · PI Janet Ellen Dancey · 2014 to 2026
$40.4M
NCI NIH HHS U10 CA180863
6 · The paper itself

Abstract

Background: Celecoxib and low-dose aspirin might decrease risk of breast cancer recurrence. Methods: In the Canadian Cancer Trials Group MA.27, postmenopausal hormone receptor-positive breast cancer patients were randomly assigned (2 × 2) to adjuvant exemestane or anastrozole, and celecoxib or placebo. Low-dose aspirin of 81 mg or less was a stratification factor. Due to concerns about cardiac toxicity, celecoxib use was stopped in December 2004, while stratification by aspirin use was removed through protocol amendment. We examined the effects of celecoxib and low-dose aspirin on event-free survival (EFS), defined as time from random assignment to time of locoregional or distant disease recurrence, new primary breast cancer, or death from any cause; distant disease-free survival (DDFS); and overall survival (OS). All statistical tests were two-sided. Results: Random assignment to celecoxib (n = 811, 50.0%) or placebo (n = 811, 50.0%) was discontinued after 18 months (n = 1622). At a median of 4.1 years' follow-up, among 1622 patients, 186 (11.5%) patients had an EFS event: 80 (4.9%) had distant relapse, and 125 (7.7%) died from any cause. Celecoxib did not statistically significantly impact EFS, DDFS, or OS in univariate analysis (respectively, P = .92, P = .55, and P = .56) or multivariable analysis (respectively, P = .74, P = .60, and P = .76). Low-dose aspirin use (aspirin users n = 476, 21.5%; non-aspirin users n = 1733, 78.5%) was associated in univariate analyses with worse EFS (hazard ratio [HR] = 1.48, 95% confidence interval [CI] = 1.12 to 1.96, P = 0.006) and worse OS (HR = 1.87, 95% CI = 1.35 to 2.61, P < .001). After adjusting for baseline characteristics and treatment arm, aspirin use showed no statistical association with EFS (P = .08) and DDFS (P = .82), but was associated with statistically worse OS (HR = 1.67, 95% CI = 1.13 to 2.49, P = .01). Conclusion: Random assignment to short-term (≤18 months) celecoxib as well as use of low-dose aspirin showed no effect on DDFS and EFS in multivariable analysis. Low-dose aspirin increased "all-cause" mortality, presumably because of higher preexisting cardiovascular risks.

Indexed as

AdultAgedBiomarkers, TumorBreast NeoplasmsCelecoxibChemotherapy, AdjuvantCombined Modality TherapyCyclooxygenase 2 InhibitorsFemaleHumansKaplan-Meier EstimateMiddle AgedNeoplasm StagingTreatment OutcomeBiomarkers, TumorCelecoxibCyclooxygenase 2 Inhibitors

Identifiers

PMID29554282
PMCPMC6669949
OpenAlexW2789727858

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.